Compare Medpace Holdings Inc (MEDP) vs SS&C Technologies Holdings Inc. Common Stock (SSNC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs SS&C Technologies Holdings Inc. Common Stock — how do they compare? Medpace Holdings Inc trades at $616.98 (market cap $17.21B), while SS&C Technologies Holdings Inc. Common Stock trades at $82.5 (market cap $19.25B). The key difference: Medpace Holdings Inc and SS&C Technologies Holdings Inc. Common Stock are close in size by market cap, and SS&C Technologies Holdings Inc. Common Stock pays a 1.46% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and SS&C Technologies Holdings Inc. Common Stock for 0 Days on average.
| MEDP | SSNC | |
|---|---|---|
Market Cap | $17.21B | $19.25B |
Volume | 311,245 | 1,341,767 |
Sector | Health | Technology |
52-Week High | $630.19 | $89.62 |
52-Week Low | $393.42 | $62.05 |
Typical Hold Time | 14 Days | 0 Days |
Enterprise Value | $16.83B | $26.59B |
Dividend Yield | — | 1.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $609.89, down 1.64% today, with a bullish technical signal and strong support near $606. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue grew to $2.53B in 2025, with a net income margin of 17.67%. Recent news highlights CEO stock sales and institutional position adjustments.
Outlook remains positive with a consensus price target of $620.44, offering modest upside. Key risks include high valuation multiples and insider selling. Earnings growth and sector demand are primary catalysts, but investor caution is warranted given elevated P/E and P/B ratios.
SSNC trades at $81.52, up 0.65% on the day, with a neutral technical signal. The company has consistently beaten earnings estimates in recent quarters (Q4 2025, Q1 2026, Q2 2026) and shows solid fundamentals, including a 13.16% net income margin and 12.73% ROE. Recent news highlights new client wins and AI-driven product enhancements, reinforcing its market position.
The outlook is positive, supported by strong analyst consensus (70.83% Buy rating) and a $91.50 price target, implying ~12% upside. Key risks include execution of growth initiatives and competitive pressures in the financial technology sector. The stock presents a compelling opportunity for investors seeking a fundamentally sound company with recurring revenue streams.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About SS&C Technologies Holdings Inc. Common Stock
SS&C Technologies Holdings, Inc. provides software and outsourced services for financial services and healthcare organizations, covering fund accounting, portfolio management, trading support, and regulatory reporting, and operates as a hedge fund and private equity administrator and mutual fund transfer agent.
Read more on SSNC →
